Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2026-04-29 16:46:07 ET · period of report 2026-04-28 · accession 0001384243-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-29 16:46 | 2026-04-28 | KNSA | Quart Barry D | Dir | M - OptEx | $14.33 | +13.1K | 25.6K | +104% | +$187.7K |
| DT | 2026-04-29 16:46 | 2026-04-28 | KNSA | Quart Barry D | Dir | S - Sale+OE | $50.10 | -13.1K | 12.5K | -51% | -$656.3K |
| DT | 2026-04-29 16:46 | 2026-04-28 | KNSA | Quart Barry D | Dir | M - OptEx | $0.00 | -13.1K | 13.2K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2026-04-28 | M | A | 13,099 | $14.33 | 25,645 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. |
| 2 | Common | Class A Ordinary Share | 2026-04-28 | S | D | 13,099 | $50.10 | 12,546 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.00 and $50.725. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 3 | Derivative | Share Option | 2026-04-28 | M | D | 13,099 | $0.00 | 13,237 | D | $14.33 · — to 2031-06-28 | 13,099 Class A Ordinary Shares | (F1) This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. (F3) The option is fully vested and exercisable. |